These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 8437967)
1. Omeprazole: a comprehensive review. Massoomi F; Savage J; Destache CJ Pharmacotherapy; 1993; 13(1):46-59. PubMed ID: 8437967 [TBL] [Abstract][Full Text] [Related]
2. Clinical utility and safety of omeprazole. Walan A Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279 [TBL] [Abstract][Full Text] [Related]
3. Omeprazole: a new approach to gastric acid suppression. Buhl K; Clearfield HR Am Fam Physician; 1990 Apr; 41(4):1225-7. PubMed ID: 2321497 [TBL] [Abstract][Full Text] [Related]
4. [Omeprazole in the therapy of acid-induced diseases]. Simon B; Dammann HG; Müller P Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299 [TBL] [Abstract][Full Text] [Related]
5. Lansoprazole: a comprehensive review. Zimmermann AE; Katona BG Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323 [TBL] [Abstract][Full Text] [Related]
6. Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase. McArthur KE; Jensen RT; Gardner JD Annu Rev Med; 1986; 37():97-105. PubMed ID: 3010811 [TBL] [Abstract][Full Text] [Related]
7. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Clissold SP; Campoli-Richards DM Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658 [TBL] [Abstract][Full Text] [Related]
8. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Barradell LB; Faulds D; McTavish D Drugs; 1992 Aug; 44(2):225-50. PubMed ID: 1382017 [TBL] [Abstract][Full Text] [Related]
9. Clinical experience with omeprazole: assessment of efficacy and safety. Walan A J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359 [TBL] [Abstract][Full Text] [Related]
10. [Substituted benzimidazoles--a new dimension in ulcer therapy?]. Fimmel CJ; Blum AL Wien Klin Wochenschr; 1984 Feb; 96(4):149-53. PubMed ID: 6324498 [TBL] [Abstract][Full Text] [Related]
11. [Lansoprazole--profile of a new proton pump inhibitor]. Seifert E Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467 [TBL] [Abstract][Full Text] [Related]
12. [Omeprazole--a drug-blocking proton pump of the parietal cells of the stomach]. Sosnowski M Pol Tyg Lek; 1985 Dec 23-30; 40(51-52):1469-72. PubMed ID: 3008128 [No Abstract] [Full Text] [Related]
13. The role of omeprazole in healing and prevention of reflux disease. Klinkenberg-Knol EC Hepatogastroenterology; 1992 Feb; 39 Suppl 1():27-30. PubMed ID: 1577392 [TBL] [Abstract][Full Text] [Related]
14. [Omeprazole. Its pharmacology and therapeutic efficacy]. Protzer U; Holtermüller KH Dtsch Med Wochenschr; 1993 Feb; 118(7):230-9. PubMed ID: 8440164 [No Abstract] [Full Text] [Related]
16. An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. Bown RL Int J Clin Pract; 2002 Mar; 56(2):132-9. PubMed ID: 11926700 [TBL] [Abstract][Full Text] [Related]
17. [Strong inhibition of gastric acid secretion: when is it justifiable?]. Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653 [No Abstract] [Full Text] [Related]
18. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. Meijer JL; Jansen JB; Lamers CB Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060 [TBL] [Abstract][Full Text] [Related]